Le Lézard
Classified in: Health
Subjects: FDA, IMA

Rehabtronics Receives Certification for Medical Device Single Audit Program (MDSAP), Expediting Global Commercialization of its Upper Limb Rehabilitation Devices


This Quality Assurance Certification confirms Rehabtronics has achieved regulatory audit and compliance requirements in numerous countries including the United States and Canada.

VANCOUVER, BC, Jan. 3, 2024 /PRNewswire/ -- Rehabtronics Inc announces it has successfully upgraded its ISO13485:2016 quality certification to include the internationally-recognized Medical Device Single Audit Program (MDSAP) standard. The additional certification confirms the company's medical device manufacturing program achieves the regulatory audit requirements and compliance standards of Australia, Canada, and the United States.

"This certification is an important milestone for our company as it streamlines and expedites our efforts to seek regulatory approval to bring our rehabilitation products to new markets," says Bojana Turic, Chief Scientific Officer-Regulatory Affairs. "By attesting that our products adhere to the highest quality standards set by regulatory bodies including the US FDA and Health Canada, MDSAP certification reduces barriers and saves us valuable time and resources."

Rehabtronics currently has regulatory clearance in Europe, Asia, and the United States for its Class II neurorehabilitation products that assist patients in recovering movements after central or peripheral nervous system injury or disease. Prelivia, its newest product designed to alleviate pressure injuries, has been cleared by the US FDA and is pending Health Canada approval.

"Obtaining this certification will allow us to bring our Class II products to Canadians," says Rehabtronics CEO Rahul Samant. "We're excited about making our technology easily accessible to more patients beginning 2024"

ABOUT REHABTRONICS

Rehabtronics develops medical devices that restore function and improve the lives of people who are paralyzed or immobile. Founded in 2003 as a spinoff from the Neuroscience Institute of the University of Alberta, Rehabtronics is dedicated to bringing neuroscience discoveries into clinical practice. Prelivia, the company's newest product, is designed to alleviate pressure injuries, one of the deadliest hospital-acquired injuries. Its rehabilitation devices help people recover movement after central or peripheral nervous system injury or disease.  www.rehabtronics.com.

Media Contact

Neha Doshi
Marketing Manager
[email protected]
780-701-5167

SOURCE Rehabtronics Inc.


These press releases may also interest you

at 11:30
The National Alliance on Mental Illness Greater L.A. County (NAMI GLAC) will celebrate its 20th annual NAMIWalks Greater LA County Mental Health Festival during Mental Health Awareness Month on Saturday, May 4, 2024. This free community wide event at...

at 10:30
Flourishing Foundations Recovery has launched a new outpatient detox center in San Antonio, TX, aiming to help individuals tackle drug and alcohol addiction without pausing their daily lives. The new substance abuse treatment center ensures easy...

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...



News published on and distributed by: